+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating empasiprubart for adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a condition causing nerve inflammation and muscle weakness. This Phase 3 randomized, double-blinded, placebo-controlled study aims to demonstrate the efficacy and safety of empasiprubart in treating CIDP. The study is sponsored by argenx and includes adults diagnosed with typical or variant forms of CIDP who have active disease and residual disability. Participants are randomly assigned in part A to receive either empasiprubart or a placebo by intravenous infusion for 24 weeks 6 months. After part A, all participants enter part B, where everyone receives empasiprubart for 96 weeks 24 months. Participants who received empasiprubart in part A will receive a placebo infusion once during part B to maintain blinding. Throughout the study, participants will undergo regular assessments including the adjusted Inflammatory Neuropathy Cause and Treatment aINCAT score, grip strength measurements, muscle strength evaluations, and quality of life questionnaires. Researchers will monitor changes from baseline in motor function, disability, and symptom severity up to 24 weeks in part A and continue evaluations through part B. Safety measures include tracking adverse events and immune responses. The total participation duration can last up to 120 weeks approximately 30 months.

Age: 18Years +All GendersPhase 3
89 locations
S

Actively Recruiting

Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
566 locations
P

Actively Recruiting

This research aims to compare two asthma inhalers that use different propellants in people with mild to moderate asthma. The study evaluates whether an investigational inhaler with a new climate-friendly propellant, HFA-152a, works as safely and effectively as inhalers using the existing HFA-134a propellant. This global Phase II study plans to enroll 468 patients in Europe, Latin America, Ukraine, South Africa, and the United Kingdom. Participants will use one of three inhaler treatments in a randomized, double-blind crossover design the investigational CHF5993 pMDI with HFA-152a, CHF5993 pMDI with HFA-134a, or CHF718 pMDI with HFA-134a. Each inhaler is taken as two puffs twice daily. The study compares lung function effects of these inhalers during treatment periods. During the trial, participants will be assessed for lung function through measurements like forced expiratory volume in 1 second FEV1 at baseline and after treatment. Researchers will monitor safety, treatment adherence, and asthma control over the study period. Participants undergo scheduled visits for these evaluations, with the study expected to complete in June 2027.

Age: 18Years - 75YearsAll GendersPhase 2
167 locations